Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Brilinta Sales"

23:40 EDT 24th July 2014 | BioPortfolio

Original Source: Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It reduces the clumping of blood particles, called platelets,...

Matching Channels

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Sales Jobs

Pfizer

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have...

Boehringer Ingelheim

Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales.  With bases in 47 c...

Plavix

Plavix is a clot-busting drug, produced by Bristol-Myers Squibb Company, and reached annual sales in 2009 of $4.2m, making the third highest drug in the world (based on 2009 annual sales). Prescri...

Matching News

AstraZeneca Makes Progress on Global Brilinta Trial

AstraZeneca announced it has completed patient enrollment approximately four months ahead of plan in the Phase 3 clinical trial EUCLID studying Brilinta (ticagrelor) table

Brilinta: Completed Phase IIIb enrollment

UPDATE 1-AstraZeneca earnings heading south as patent losses bite

* Brilinta experienced headwinds after U.S. investigation

Lilly Rejects NICE Comparator For Efient In ACS, But Gains Approval Anyway

Despite Lilly's decision not to make an indirect comparison its chosen comparator, AstraZeneca’s Brilinta, NICE agrees that Lilly's Efient is cost-effective and sometimes clinically superior to stan...

AstraZeneca Says Revamped Pipeline Will Return It To Health, But Pitfalls Remain

Equipped with 19 drug candidates for Phase III trials over the next two years, Britain’s AstraZeneca says it’s finally “on a roll.” But the troubled medicine maker still expects earnings to ke...

AstraZeneca Closes Patient Enrollment Four Months Ahead Of Plan In EUCLID Study

LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L) announced it has completed patient enrollment approximately four months ahead of plan in the Phase III clinical trial EUCLID studying BRILINTA (ticagrel...

GSK First Foreign Pharma To Stop Kickbacks For Drug Sales

GSK is making drastic reforms on its sales practices in China, and announced it would stop paying its sales representatives according to their sales.

Using Your Story and Not Technique to Achieve Sales Success

Riverside, CA (PRWEB) July 23, 2014 “Unlike most Sales Training Programs, the Sales Success Summer Series will focus on developing your own unique gifts, talents and abilities as opposed to gi...

Matching PubMed Articles

Sellers, shakers, peddlers, and hawkers: rehabilitation of sales workers.

Sales workers persuade, influence, inform and cajole customers, resulting in the purchase of a product or service. The selling profession is broken down into three categories: sales technology, genera...

Variations in the sales and sales patterns of veterinary antimicrobial agents in 25 European countries.

To describe sales and sales patterns of veterinary antimicrobial agents in 25 European Union (EU)/European Economic Area (EEA) countries for 2011.

The effect of consignment to broodmare Sales on physiological stress measured by faecal glucocorticoid metabolites in pregnant Thoroughbred mares.

Validation of a method for the minimally-invasive measurement of physiological stress will help understanding of risk factors that may contribute to stress-associated events including recrudescence of...

Ticagrelor (brilinta) for secondary prevention of thrombotic events following acute coronary syndrome.

Ariad suspends ponatinib sales.

Because of concerns about serious cardiovascular side effects, the U.S. Food and Drug Administration asked Ariad Pharmaceuticals to temporarily suspend sales and marketing of ponatinib to treat chroni...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement